LG Chem Ltd. will spend at least $3 billion to build its first US cathode plant in Tennessee in response to the growing demand for electric vehicle (EV) components.
The cathode manufacturing facility will be capable of producing 120,000 tons a year by 2027, which would be enough to power 1.2 million pure EVs with a range of 500 kilometers per charge.
The construction will start in the first quarter of next year on a property stretching 1.7 million square meters. The plant will go into operation at the end of 2025.
According to LG Chem CEO Shin Hak-cheol, the cathode manufacturing facility brings them one step closer to becoming the world’s best battery materials manufacturer and fulfilling their corporate vision to become a top global science company.
The Inflation Reduction Act will require EV batteries to be made with higher portions of minerals processed or mined in the US, or countries with free trade pacts with the US.
LG Chem said it aims to boost its sales in the battery materials segment by fourfold to 20 trillion won by 2027 from 5 trillion won in 2022.


Rice feeds billions of people – but its role in fueling climate change is growing
Qualcomm Stock Jumps on Amazon AI Chip Deal
Optus Apologises After Network Outage Disrupts Emergency Calls
OpenAI Weighs AI Development Slowdown Over Safety Risks
Wildfires ignite infection risks, by weakening the body’s immune defences and spreading bugs in smoke
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador
Apple Unveils $1,999 Foldable iPhone Duo
Australia Plans New Rules Giving Users Control Over Social Media Feeds
What’s so special about Ukraine’s minerals? A geologist explains
White House Weighs Refined Copper Tariffs as Cost Concerns Grow
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota
Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites
We combed through old botanical surveys to track how plants on Australia’s islands are changing
U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 



